| 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 145.22亿元 | 116.53亿元 | 21 124 | | 净资产 | 31.16亿元 | 38.68亿元 | 46 124 | | 净利润 | 4703.03万元 | 1.65亿元 | 62 124 | | 市盈率(动) | 154.39 | 94.97 | 79 124 | | 市净率 | 4.66 | 3.79 | 97 124 | | 毛利率 | 62.08% | 51.33% | 50 124 | | 净利率 | 4.88% | 10.4% | 82 124 | | ROE | 1.5% | 2.18% | 76 124 | 证券之星消息，截至2025年10月24日收盘，开立医疗(300633)报收于33.56元，上涨2.04%，换手率 1.22%，成交量5.29万手，成交额1.78亿元。 10月24日的资金流向数据方面，主力资金净流出2187.8万元，占总成交额12.31%，游资资金净流出 474.44万元，占总成交额2.67%，散户资金净流入2662.24万元 ...

证券之星消息，截至2025年10月15日收盘，开立医疗(300633)报收于34.24元，上涨2.24%，换手率 1.17%，成交量5.04万手，成交额1.71亿元。 10月15日的资金流向数据方面，主力资金净流入513.26万元，占总成交额3.0%，游资资金净流出123.7 万元，占总成交额0.72%，散户资金净流出389.56万元，占总成交额2.28%。 近5日资金流向一览见下表： 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 | 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 148.16亿元 | 118.79亿元 | 21 123 | | 净资产 | 31.16亿元 | 38.89亿元 | 47 123 | | 净利润 | 4703.03万元 | 1.49亿元 | 60 123 | | 市盈率(动) | 157.52 | 67.67 | 81 123 | | 市净率 | 4.76 | 3.82 | 96 123 | | 毛利率 | 62.08% | 51.85% | 50 ...

| 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 144.92亿元 | 117.95亿元 | 21 123 | | 净资产 | 31.16亿元 | 38.89亿元 | 47 123 | | 净利润 | 4703.03万元 | 1.49亿元 | 60 123 | | 市盈率(动) | 154.07 | 66.45 | 81 123 | | 市净率 | 4.65 | 3.78 | 96 123 | | 毛利率 | 62.08% | 51.85% | 50 123 | | 净利率 | 4.88% | 10.39% | 84 123 | | ROE | 1.5% | 1.8% | 75 123 | 证券之星消息，截至2025年10月14日收盘，开立医疗(300633)报收于33.49元，下跌1.82%，换手率 0.84%，成交量3.65万手，成交额1.23亿元。 10月14日的资金流向数据方面，主力资金净流出236.31万元，占总成交额1.91%，游资资金净流入 294.81万元，占总成交额2.39%，散户资金净流出58.49万元，占总 ...

Group 1 - The stock of KAILI Medical (300633) closed at 35.78 yuan on September 16, 2025, with no change in price, a turnover rate of 1.05%, a trading volume of 45,600 lots, and a transaction amount of 162 million yuan [1] - On September 16, the net outflow of main funds was 12.4 million yuan, accounting for 7.67% of the total transaction amount, while the net inflow of retail funds was 2.61 million yuan, accounting for 1.62% of the total transaction amount [1] - The company reported a main business income of 964 million yuan for the first half of 2025, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, a year-on-year decrease of 72.43% [2] Group 2 - KAILI Medical's total market value is 15.482 billion yuan, which is higher than the industry average of 12.274 billion yuan, ranking 22 out of 123 in the medical device industry [2] - The company's net profit margin is 4.88%, which is lower than the industry average of 10.39%, ranking 84 out of 123 [2] - In the last 90 days, 18 institutions rated the stock, with 12 buy ratings and 6 hold ratings, and the average target price set by institutions is 40.17 yuan [3]

Group 1 - The stock of Kaili Medical (300633) closed at 32.33 yuan on September 5, 2025, with an increase of 2.31% and a trading volume of 31,200 hands, totaling 100 million yuan in transaction value [1] - On September 5, the net outflow of main funds was 1.5851 million yuan, accounting for 1.58% of the total transaction value, while the net inflow of speculative funds was 2.8629 million yuan, accounting for 2.86% [1] - The company's main business includes the independent research, development, production, and sales of medical diagnostic and treatment equipment [2] Group 2 - Kaili Medical's total market value is 13.99 billion yuan, which is higher than the industry average of 11.933 billion yuan, ranking 25th out of 123 in the medical device industry [2] - The company's net profit for the first half of 2025 was 47.03 million yuan, a decrease of 72.43% year-on-year, with a gross profit margin of 62.08% [2] - In the last 90 days, 18 institutions rated the stock, with 12 buy ratings and 6 hold ratings, and the average target price set by institutions is 40.17 yuan [3]

Core Viewpoint - The stock of Kaili Medical (300633) has shown a decline in both price and key financial metrics, indicating potential challenges in its operational performance and market perception [1][3]. Financial Performance - As of September 4, 2025, Kaili Medical's stock closed at 31.6 yuan, down 1.31% with a trading volume of 40,500 lots and a total transaction amount of 129 million yuan [1]. - The company reported a main revenue of 964 million yuan for the first half of 2025, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% year-on-year [3]. - The second quarter of 2025 saw a single-quarter main revenue of 534 million yuan, a slight increase of 0.17% year-on-year, but the net profit decreased by 44.65% to 38.96 million yuan [3]. Market Sentiment and Trading Activity - On September 4, 2025, the net outflow of main funds was 13.51 million yuan, accounting for 10.47% of the total transaction amount, while retail investors saw a net inflow of 15.22 million yuan, representing 11.80% of the total [1][2]. - Over the past five days, the stock has experienced a consistent trend of net outflows from main and speculative funds, indicating a bearish sentiment among institutional investors [2]. Industry Comparison - Kaili Medical's total market capitalization is 13.674 billion yuan, which is higher than the industry average of 11.766 billion yuan, ranking 25th out of 123 companies in the medical device sector [3]. - The company's price-to-earnings ratio (P/E) stands at 145.37, significantly higher than the industry average of 65.27, indicating potential overvaluation [3]. - The gross margin of Kaili Medical is 62.08%, which is above the industry average of 51.85%, but its net profit margin of 4.88% is below the industry average of 10.39% [3]. Analyst Ratings - In the last 90 days, 17 institutions have rated the stock, with 12 buy ratings and 5 hold ratings, suggesting a generally positive outlook despite recent performance issues [4]. - The average target price set by analysts over the past 90 days is 40.17 yuan, indicating potential upside from the current trading price [4].

Core Viewpoint - The stock of Kaili Medical (300633) has experienced a decline, with significant net outflows from major funds, indicating potential concerns among institutional investors [1][2]. Financial Performance - As of August 27, 2025, Kaili Medical's stock closed at 32.93 yuan, down 2.75% with a trading volume of 82,500 lots and a turnover of 276 million yuan [1]. - The company reported a main revenue of 964 million yuan for the first half of 2025, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% year-on-year [3]. - The second quarter of 2025 saw a main revenue of 534 million yuan, a slight increase of 0.17% year-on-year, but the net profit decreased by 44.65% to 38.96 million yuan [3]. Market Position and Ratios - Kaili Medical's total market capitalization is 14.249 billion yuan, with a net asset value of 3.116 billion yuan, and a net profit of 47.03 million yuan, ranking 58th in the medical device industry [3]. - The company's price-to-earnings ratio (P/E) stands at 151.49, significantly higher than the industry average of 73.16, indicating a potential overvaluation [3]. - The gross margin is reported at 62.08%, which is above the industry average of 51.64%, while the net margin is at 4.88%, below the industry average of 11.01% [3]. Fund Flow Analysis - On August 27, 2025, the net outflow of major funds was 14.89 million yuan, accounting for 5.4% of the total turnover, while retail investors saw a net inflow of 782,300 yuan, representing 0.28% of the total turnover [1][2]. - Over the past five days, the stock has seen fluctuating fund flows, with significant net outflows from major funds on multiple days, indicating a trend of institutional selling [2]. Analyst Ratings - In the last 90 days, 15 institutions have rated the stock, with 12 buy ratings and 3 hold ratings, suggesting a generally positive outlook despite recent performance [4]. - The average target price set by analysts over the past 90 days is 42.65 yuan, indicating potential upside from the current trading price [4].

Core Viewpoint - The stock of Kailing Medical (300633) has shown a recent increase in price, with a closing price of 35.65 yuan on August 21, 2025, reflecting a 3.36% rise, despite a decline in net profit and revenue in the latest financial report [1][4]. Financial Performance - Kailing Medical reported a main revenue of 964 million yuan for the first half of 2025, a year-on-year decrease of 4.78% [4]. - The net profit attributable to shareholders was 47.03 million yuan, down 72.43% year-on-year [4]. - The second quarter of 2025 saw a main revenue of 534 million yuan, a slight increase of 0.17% year-on-year, while the net profit for the quarter was 38.96 million yuan, down 44.65% [4]. Market Activity - On August 21, 2025, the stock experienced a net inflow of main funds amounting to 18.73 million yuan, which constituted 5.88% of the total transaction volume [1]. - Over the past five days, the stock has seen fluctuations in fund flows, with notable net outflows from retail investors [1][2]. Financing and Margin Trading - On August 21, 2025, the financing buy-in was 35.58 million yuan, with a net buy of 15.55 million yuan [1][2]. - The total margin trading balance stood at 138 million yuan, with a margin balance of 1.06 million yuan [1][2]. Industry Comparison - Kailing Medical's total market capitalization is 15.43 billion yuan, compared to the industry average of 12.24 billion yuan [4]. - The company's net profit margin is 4.88%, significantly lower than the industry average of 10.85% [4]. - The price-to-earnings ratio for Kailing Medical is 164, compared to the industry average of 72.23, indicating a higher valuation relative to earnings [4]. Analyst Ratings - In the last 90 days, 10 institutions have rated Kailing Medical, with 8 buy ratings and 2 hold ratings, and the average target price set at 41.6 yuan [5].

Financial Performance - For the first half of 2025, the company's operating revenue was approximately 964.26 million yuan, a decrease from 1,012.69 million yuan in the same period last year, representing a decline of about 4.78% [1] - The net profit attributable to shareholders was approximately 47.03 million yuan, down from 170.57 million yuan year-on-year, indicating a significant drop of about 72.49% [1] - The net profit after deducting non-recurring gains and losses was approximately 39.88 million yuan, compared to 154.94 million yuan in the previous year, a decrease of about 74.30% [1] - The basic earnings per share were 0.1087 yuan, down from 0.3956 yuan year-on-year [1] - The weighted average return on equity was 1.50%, a decline of 3.80 percentage points compared to the previous year [19] Cash Flow and Assets - The net cash flow from operating activities was -250.30 million yuan, a decrease of 265 million yuan compared to the previous year [22] - Total assets at the end of the reporting period were approximately 4,017.77 million yuan, down from 4,312.99 million yuan at the end of the previous year [1] - The company experienced a 99.66% decrease in trading financial assets compared to the end of the previous year, while inventory increased by 20.61% [34] Shareholder Structure - As of the end of the first half of 2025, the top ten shareholders included a new shareholder, Guangfa High-end Manufacturing Equity Fund, replacing the previous quarter's shareholder [51] - The Social Security Fund 17022 portfolio and several healthcare-focused funds increased their holdings [51] Valuation Metrics - As of August 21, the company's price-to-earnings ratio (TTM) was approximately 818.18 times, the price-to-book ratio (LF) was about 4.95 times, and the price-to-sales ratio (TTM) was around 7.85 times [1]

Core Insights - The core viewpoint of the news is that Kaili Medical has experienced a significant decline in its operating performance in the first half of 2025, with indications of a potential recovery in the second quarter. Financial Performance - In the first half of 2025, Kaili Medical reported operating revenue of 964 million yuan, a year-on-year decrease of 4.78% [1] - The net profit attributable to shareholders was 47 million yuan, a substantial year-on-year decline of 72.43% [1] - The second quarter net profit attributable to shareholders was 39 million yuan, showing a significant quarter-on-quarter increase of 382.45% [1] Profitability Indicators - The net profit margin dropped from 16.84% in the first half of 2024 to 4.88% in 2025 [3] - The gross profit margin decreased from 67.43% to 62.08% [3] - The return on equity fell by 3.80 percentage points to 1.50% [3] Operational Stability - Kaili Medical faced inventory management pressures, with inventory turnover days reaching 354.68 days, an increase of 46.46% year-on-year [5] - The net cash flow from operating activities was -250 million yuan, a shift from a positive 15 million yuan in the same period of 2024 [5] - The asset-liability ratio for the first half of 2025 was 22.46%, a year-on-year decrease of 1.23 percentage points, indicating better control over debt levels [5] Institutional Holdings - As of the first half of 2025, the number of institutions holding Kaili Medical's stock was 32, a significant decrease of 312 from 344 in the same period of 2024 [8] - The highest market capitalization of Kaili Medical was 26.967 billion yuan on June 9, 2023, while the current market capitalization is 15.426 billion yuan, indicating a required stock price increase of 74.82% to reach the historical peak [8] - Despite the challenges, the stock price has increased by 21.67% year-to-date, reflecting some market confidence in the company's long-term prospects [8]